A Phase II Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2018
Price : $35 *
At a glance
- Drugs Idelalisib (Primary) ; Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 10 Dec 2018 Status changed from suspended to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 30 Mar 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Jun 2018.